HIND (Vyome Holdings) Moat Score: 1/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HIND Vyome Holdings Inc HIND
11 GF Score
Price $1.99
! 2 Warning Signs
View Full Analysis

What is Vyome Holdings Moat Score?

Vyome Holdings HIND -0.50% 11 Moat Score is 1 as of Jul. 29, 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,393 Biotechnology companies, Vyome Holdings ranks worse than 52.33% on this metric.

Vyome Holdings has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Vyome Holdings has No Moat: HIND lacks discernible competitive advantages. It operates in a highly competitive market with no significant intellectual property, brand strength, or cost advantages.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Vyome Holdings might have No Moat - Very weak/transient advantages.

Vyome Holdings  (NAS:HIND) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Vyome Holdings Moat Score Related Terms

HIND vs CTXR, MBRX, AKTX: Moat Score Comparison

For the Biotechnology subindustry, Vyome Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vyome Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vyome Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Vyome Holdings's Moat Score falls into.


HIND
11GF Score
Vyome Holdings Inc HIND
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Vyome Holdings (HIND) has a Moat Score of 1 as of Jul. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Vyome Holdings ranks #729 out of 1393 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Vyome Holdings' Moat Score too high?
Vyome Holdings' current Moat Score is 1. The Biotechnology industry median Moat Score is 2.00. Vyome Holdings' value of 1 is 50% below this industry median. Based on the distribution chart, Vyome Holdings ranks #729 out of 1393 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' Moat Score compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #729 out of 1393 companies for Moat Score. This places Vyome Holdings in the lower half of its industry. The industry median Moat Score is 2.00. Vyome Holdings' value of 1 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vyome Holdings's current Moat Score of 1 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vyome Holdings's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current Moat Score of 1. The current Moat Score is 1 and 50% below the Biotechnology industry median of 2.00. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Vyome Holdings (HIND), the current Moat Score is 1 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vyome Holdings Business Description

Address Harvard Square, Suite 400, One Mifflin Place, Cambridge, MA, USA, 02138
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score

Get the complete analysis for HIND

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price